Clinical Trial Update: Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether dapagliflozin can reduce atrial fibrillation burden in patients undergoing catheter ablation; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: University of Rochester | Conditions: Atrial Fibrillation | Phase 4 | Status: COMPLETED | Results posted: 2024-12-04